Key Takeaways
- • Inflexion agrees to sell a majority stake in Celnor Group, a TICC (technology, information, communications and consulting) business, to Goldman Sachs Alternatives, according to PE Hub Europe reporting dated 23 October 2026.
- • Celnor employs more than 2,750 people across 60 locations and generates annual revenues exceeding £300m.
- • Blue Point Capital, Gimv and Bencis Capital Partners are all reported to be drawn to the equine healthcare sector.
- • The story is a commentary piece by Nina Lindholm and does not disclose deal financials beyond Celnor's headcount and revenue scale.
Summary
Inflexion has agreed to sell a majority stake in Celnor Group to Goldman Sachs Alternatives, according to a PE Hub Europe commentary by Nina Lindholm published on 23 October 2026. The transaction, which the article lists under business services and healthcare, involves a business the report describes as a TICC operation. Celnor employs more than 2,750 people across 60 locations and generates annual revenues exceeding £300m, placing it among the larger assets in Inflexion's portfolio of mid-market services businesses.
The same commentary turns to equine healthcare, a niche sector that has attracted interest from several private equity investors. Blue Point Capital, Gimv and Bencis Capital Partners are identified as firms drawn to the space. The article presents the sector as an emerging area of private capital interest, though the source material provides limited detail on specific transactions, valuations or target companies involved in those pursuits.
For institutional allocators, the Celnor sale signals continued appetite from large alternative asset managers such as Goldman Sachs Alternatives for scaled, cash-generating services businesses with a global operating footprint. The equine healthcare references point to growing private capital focus on niche, specialised healthcare verticals. Further detail on deal terms, including the size of the stake being sold and the purchase price, was not available in the primary source.
The same commentary turns to equine healthcare, a niche sector that has attracted interest from several private equity investors. Blue Point Capital, Gimv and Bencis Capital Partners are identified as firms drawn to the space. The article presents the sector as an emerging area of private capital interest, though the source material provides limited detail on specific transactions, valuations or target companies involved in those pursuits.
For institutional allocators, the Celnor sale signals continued appetite from large alternative asset managers such as Goldman Sachs Alternatives for scaled, cash-generating services businesses with a global operating footprint. The equine healthcare references point to growing private capital focus on niche, specialised healthcare verticals. Further detail on deal terms, including the size of the stake being sold and the purchase price, was not available in the primary source.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.